Results 91 to 100 of about 276,897 (341)

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer

Scientific Reports, 2021
PD-L1 expression is the most useful predictive biomarker for immunotherapy efficacy on non-small cell lung cancer (NSCLC), and CD8+ tumor-infiltrating lymphocytes (CD8+ TILs) play an essential role in the clinical activity of immunotherapy.
Yoshihisa Shimada, Jun Matsubayashi, Yujin Kudo, Sachio Maehara, Susumu Takeuchi, Masaru Hagiwara, Masatoshi Kakihana, Tatsuo Ohira, Toshitaka Nagao, Norihiko Ikeda   +9 more
doaj   +1 more source

Day/night variations of myeloid and lymphoid cell subsets in the murine inguinal lymph node

FEBS Open Bio, EarlyView.
The circadian system is involved in the temporal regulation of the immune system. Our study reveals that two innate immune populations, NKT cells and neutrophils, predominate at the beginning of the day in healthy mice, highlighting how the time of day influences immune responses.
Paula M. Wagner, César G. Prucca, Lucia Boffelli, Virginia A. Piqueras, Silvia G. Correa, Mariana Maccioni, Mario E. Guido   +6 more
wiley   +1 more source

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective

Frontiers in Immunology, 2020
Targeting PD-L1 and PD-1 interactions is a relatively new therapeutic strategy used to treat cancer. Inhibitors of PD-1/PD-L1 include peptides, small molecule chemical compounds, and antibodies.
Libin Guo, Ran Wei, Yao Lin, Hang Fai Kwok   +3 more
doaj   +1 more source

147P PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients [PDF]

, 2021
Yinghua Yu, Leizhou Xia, Jianying Zhou, K. Wang, Y. Zhang, Chenkai Zhang, A. Liu, Yun Fan, J. Chang, L. Wang, Yihan Li, Shun Lü   +11 more
openalex   +1 more source

Alterations of immune response of non-small lung cancer with azacytidine [PDF]

, 2013
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting
Baylin, Stephen B, Brahmer, Julie R, Brock, Malcolm V, Carvajal, Richard D, De Meyer, Tim, Du, Zhengzong, Easton, Keith, Easwaran, Hariharan, Jones, Peter A, Juergens, Rosalyn A, Koch, Alexander, Laird, Peter W, Mohammad, Helai P, Pardoll, Drew, Parsana, Princy, Rodgers, Kristen, Rudin, Charles M, Taube, Janis M, Topalian, Suzanne L, Tsai, Salina, Tykodi, Scott S, Van Criekinge, Wim, Vendetti, Frank, Wang, Wei, Weisenberger, Daniel J, Wrangle, John, Yen, Ray-Whay, Zahnow, Cynthia A   +27 more
core   +1 more source

The current status of checkpoint inhibitors in metastatic bladder cancer [PDF]

, 2016
For many decades, no significant improvements could be achieved to prolong the survival in metastatic bladder cancer. Recently, systemic immunotherapy with checkpoint inhibitors (anti-PD-L1/anti-CTLA-4) has been introduced as a novel treatment modality ...
Fahmy Ahmed, Omar Ahmed, Gakis, Georgios, Mohd. Ghani @ Mamat, Khairul Asri, Stenzl, Arnulf   +3 more
core   +1 more source

Standardization of PD-L1 immunohistochemistry [PDF]

Modern Pathology, 2022
Sandra Martinez-Morilla, Myrto Moutafi, David L. Rimm   +2 more
openaire   +2 more sources

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

FEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold, Janik Riese, Lancelot Seillier, Mark Kühnel, Julia Pannhausen, Charlotte O. J. Fröhlich, Christian Martin, Peter Boor, Matthias Saar, Danny D. Jonigk, Nadine T. Gaisa, Michael Rose   +11 more
wiley   +1 more source

The significance of programed cell death‐ligand 1 expression in vestibular schwannoma

Brain and Behavior, 2023
Background The association between programed cell death‐ligand 1 (PD‐L1) and tumor‐infiltrating lymphocytes (TILs) in vestibular schwannoma (VS) has been investigated in a few studies.
Se A Lee, Susie Chin, Shin Jung, Kyung‐Hwa Lee, Kyung‐Sub Moon, Jong Dae Lee   +5 more
doaj   +1 more source

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival : an updated analysis of KEYNOTE-010 trial

, 2019
Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC).
Ahn, M-J, Baas, P, de Castro, G, Jr, Dubos Arvis, C, Emancipator, K, Felip, E, Fidler, MJ, Garon, EB, Garrido, M, Han, J-Y, Herbst, RS, Jensen, EH, Kim, D-W, Kim, J-H, Lubiniecki, GM, Majem, M, Molina, JR, Perez-Gracia, JL, Samkari, A, Shentu, Y, Surmont, Veerle   +20 more
core   +1 more source